These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 23323645

  • 21. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [Abstract] [Full Text] [Related]

  • 22. Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
    Elster MJ.
    J Comput Assist Tomogr; 2013 Jul; 37(5):694-7. PubMed ID: 24045242
    [Abstract] [Full Text] [Related]

  • 23. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
    Arnaud FX, Hissene A, Métivier D, Dutasta F, Berets O, N'guema B, A'teriitéhau C, Baccialone J, Potet J.
    J Neuroradiol; 2012 Oct; 39(4):267-70. PubMed ID: 22341620
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
    Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, Clifford D, Belachew S.
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
    [Abstract] [Full Text] [Related]

  • 29. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
    Valenzuela RM, Pula JH, Garwacki D, Cotter J, Kattah JC.
    J Neurol Sci; 2014 May 15; 340(1-2):109-11. PubMed ID: 24680560
    [Abstract] [Full Text] [Related]

  • 30. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.
    Neurology; 2013 Oct 15; 81(16):1400-8. PubMed ID: 24049136
    [Abstract] [Full Text] [Related]

  • 31. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 15; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

  • 32. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Hodel J, Bapst B, Outteryck O, Verclytte S, Deramecourt V, Benadjaoud MA, Pruvo JP, Vermersch P, Leclerc X.
    Mult Scler; 2018 Dec 10; 24(14):1902-1908. PubMed ID: 29343163
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Minimal supportive treatment in natalizumab-related PML in a MS patient.
    Lalive PH, Bridel C, Ferfoglia RI, Kaiser L, Du Pasquier R, Barkhof F, Haller S.
    J Neurol Neurosurg Psychiatry; 2015 Mar 10; 86(3):354-5. PubMed ID: 24957322
    [No Abstract] [Full Text] [Related]

  • 38. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 39. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec 30; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 40. Natalizumab-induced progressive multifocal leukoencephalopathy.
    Thaker AA, Schmitt SE, Pollard JR, Dubroff JG.
    Clin Nucl Med; 2014 Jul 30; 39(7):e365-6. PubMed ID: 24152618
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.